Rounds Report: Achaogen And Eleven To Clear Their Binaries For Substantial Gains

Summary

• The bioscience market completed the week on an optimistic note.
• Eleven Biotherapeutics continued to rally strongly into its upcoming clinical binary.
• Achaogen is most likely to earn favorable votes on the May 2nd advisory committee meeting for plazomicin. And, the drug should gain an approval for the June 25 PDUFA.

We’re emphasizing the knowable by predicting how certain people and companies will swim against the current. We’re not predicting the fluctuation in the current. - Charlie Munger

Trading Analytics

Welcome to this edition of Integrated BioSci Rounds Report for April 27, 2018. As usual, we’ll elucidate notable trading analytics for the day, recent insider transactions, and interesting market developments. Without further ado, let’s take an overall assessment of the bioscience space. As follows, the iShares of NASDAQ Biotechnology Index (NASDAQ:IBB) traded up $0.31 (+0.29%) at $105.61. Moreover, the SPDR S&P Biotech (NYSE:XBI) exchanged hands $0.58 higher at $88.42 (for +0.66% gains). It’s likely that investors were trading with a more positive sentiment for the day. Regardless of the daily inclination, there are substantial prospects in the bioscience sector: one that delivers hope for patients while rewarding supporters with substantial wealth in the long haul.

Figure 1: Notable BioSci movers. (Source: Morningstar)

Moving to specific equities,

Eleven Biotherapeutics

(NASDAQ:EBIO) - a company focusing on the innovation and commercialization of the novel molecules, Targeted Protein Therapeutics (“TPTs”) - won the highlight for the day. Following a strong momentum this week, the shares exchanged hands $0.16 higher to close the session at $2.51 (for over 6.8% profits). In addition, the stock added over 31% and 130% for the past week and previous month, respectively.

Of note, TPT is a fusion drug (an antibody linked a cytotoxic protein payload that, in and of itself, is designed for the localized cancer destruction). The said antibody zones in on specific cancer cells while the cytotoxic protein kills rogue tumors. Interestingly, TPT can be employed as either a promising single drug or in combinations with other immuno-oncology agents such as checkpoint inhibitors.

Interestingly, Eleven commenced a trial at the US National Cancer Institute (“NCI”) back on Sept. 2017

Analyst’s Disclosure:I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I like to inform our readers of Seeking Alpha's recent policy change, in which the company implemented the paywall (not only to my articles but to all articles that are published over 10-day). This is in place, as the company is, after all, a business. And, the revenues from ads are not adequate to support the high-quality research that the company is providing. If you are a REAL TIME FOLLOWER, you will be notified immediately of our new research for you to continue to benefit from our due diligence. You can also gain access to all of my old articles and much more by taking the 2-week FREE trial of my marketplace, Integrated BioSci Investing.